<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00052585</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02505</org_study_id>
    <secondary_id>UPCC #06202</secondary_id>
    <secondary_id>CDR0000258548</secondary_id>
    <nct_id>NCT00052585</nct_id>
  </id_info>
  <brief_title>Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer</brief_title>
  <official_title>A Phase II Trial Of IRESSA (NSC 715055, IND 61187) In Combination With 5-FU/LV/ CPT-11 In Patients With Advanced Or Recurrent Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of combining gefitinib with fluorouracil,&#xD;
      leucovorin, and irinotecan in treating patients who have advanced or recurrent colorectal&#xD;
      cancer. Biological therapies such as gefitinib may stop the growth of tumor cells by blocking&#xD;
      the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to&#xD;
      stop tumor cells from dividing so they stop growing or die. Combining gefitinib with&#xD;
      fluorouracil, leucovorin, and irinotecan may kill more tumor cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the safety of gefitinib, fluorouracil, leucovorin calcium, and irinotecan in&#xD;
      patients with advanced or recurrent colorectal cancer.&#xD;
&#xD;
      II. Determine the major side effects of this regimen in these patients. III. Determine the&#xD;
      response rate, progression-free survival, and overall survival of patients treated with this&#xD;
      regimen.&#xD;
&#xD;
      IV. Correlate response and other measures of outcome with epidermal growth factor receptor&#xD;
      expression and the expression of genes that impact upon pathways of fluoropyrimidine&#xD;
      cytotoxicity in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a non-randomized, open-label, multi-center study.&#xD;
&#xD;
      Patients receive oral gefitinib daily beginning on day 1, irinotecan IV over 90 minutes on&#xD;
      days 1 and 15, and leucovorin calcium IV over 2 hours and fluorouracil IV over 3-5 seconds&#xD;
      followed by a 22-hour infusion on days 1, 2, 15, and 16. Courses repeat every 28 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively complete.&#xD;
  </why_stopped>
  <start_date>October 2002</start_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grade 3 or 4 toxicity, graded using the NCI CTC version 2.0</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>95% confidence interval will be determined.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Adenocarcinoma of the Colon</condition>
  <condition>Adenocarcinoma of the Rectum</condition>
  <condition>Mucinous Adenocarcinoma of the Colon</condition>
  <condition>Mucinous Adenocarcinoma of the Rectum</condition>
  <condition>Recurrent Colon Cancer</condition>
  <condition>Recurrent Rectal Cancer</condition>
  <condition>Signet Ring Adenocarcinoma of the Colon</condition>
  <condition>Signet Ring Adenocarcinoma of the Rectum</condition>
  <condition>Stage IV Colon Cancer</condition>
  <condition>Stage IV Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (irinotecan, gefitinib, leucovorin, fluorouracil)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral gefitinib daily beginning on day 1, irinotecan IV over 90 minutes on days 1 and 15, and leucovorin calcium IV over 2 hours and fluorouracil IV over 3-5 seconds followed by a 22-hour infusion on days 1, 2, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (irinotecan, gefitinib, leucovorin, fluorouracil)</arm_group_label>
    <other_name>Campto</other_name>
    <other_name>Camptosar</other_name>
    <other_name>CPT-11</other_name>
    <other_name>irinotecan</other_name>
    <other_name>U-101440E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (irinotecan, gefitinib, leucovorin, fluorouracil)</arm_group_label>
    <other_name>Iressa</other_name>
    <other_name>ZD 1839</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (irinotecan, gefitinib, leucovorin, fluorouracil)</arm_group_label>
    <other_name>CF</other_name>
    <other_name>CFR</other_name>
    <other_name>LV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (irinotecan, gefitinib, leucovorin, fluorouracil)</arm_group_label>
    <other_name>5-fluorouracil</other_name>
    <other_name>5-Fluracil</other_name>
    <other_name>5-FU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed advanced (stage IV) or recurrent adenocarcinoma of the colon&#xD;
             or rectum&#xD;
&#xD;
          -  Must have available tissue for immunohistochemical analysis&#xD;
&#xD;
          -  At least one unidimensionally measurable lesion&#xD;
&#xD;
               -  At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan&#xD;
&#xD;
               -  Tumor marker (carcinoembryonic antigen) elevation alone is insufficient for study&#xD;
                  entry&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST less than 2 times ULN (5 times ULN if liver involvement of tumor)&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other severe or uncontrolled concurrent illness that would adversely impact the&#xD;
             safety or efficacy of study therapy&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No other prior malignancy unless curatively treated and no evidence of recurrence&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to gefitinib&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No prior chemotherapy for advanced disease&#xD;
&#xD;
          -  More than 4 weeks since other prior chemotherapy (6 weeks for nitrosoureas or&#xD;
             mitomycin) and recovered&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  At least 6 months since prior adjuvant therapy&#xD;
&#xD;
          -  No prior epidermal growth factor receptor inhibitor&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent phenytoin, carbamazepine, barbiturates, rifampin, rifapentine,&#xD;
             oxacarbazepine, modafinil, griseofulvin, or Hypericum perforatum&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter O'Dwyer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of The University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>January 24, 2003</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma, Mucinous</mesh_term>
    <mesh_term>Cystadenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

